Chemotherapy-induced peripheral neurotoxicity (CIPN): an update.

The peripheral nervous system can be vulnerable to the toxic action of several drugs since it is not protected as effectively as the central nervous system from noxious exogenous agents. Drug-induced neurotoxicity can affect the nerve fibers or the neuronal bodies (generally the dorsal root ganglia of the primary sensory neurons). Among the neurotoxic drugs antineoplastic agents represent a major clinical problem, given their widespread use and the potential severity of their toxicity. In fact, the peripheral neurotoxicity of antineoplastic agents frequently represents one of their dose-limiting side effects. Moreover, even when antineoplastic agents' peripheral neurotoxicity is not dose-limiting, its onset may severely affect the quality of life of cancer patients and cause chronic discomfort. Among the anticancer chemotherapy drugs, platinum derivates, antitubulins, thalidomide and bortezomib can induce the most severe effects on the peripheral nervous system of the treated patients. Therefore, we will review the features of chemotherapy-induced peripheral neurotoxicity (CIPN) resulting from the administration of these drugs with a focus on new classes of promising antineoplastic agents, such as epothilones and proteasome inhibitors.

[1]  H. Adelsberger,et al.  The chemotherapeutic oxaliplatin alters voltage-gated Na(+) channel kinetics on rat sensory neurons. , 2000, European journal of pharmacology.

[2]  G Cartei,et al.  Cisplatin-cyclophosphamide-mitomycin combination chemotherapy with supportive care versus supportive care alone for treatment of metastatic non-small-cell lung cancer. , 1993, Journal of the National Cancer Institute.

[3]  P. Hilkens,et al.  Chemotherapy-induced peripheral neuropathy. , 1997, Journal of the peripheral nervous system.

[4]  E. Henderson,et al.  Vincristine‐induced neuropathy , 1969, Neurology.

[5]  M. Baccarani,et al.  Neurological toxicity of long‐term (>1 yr) thalidomide therapy in patients with multiple myeloma , 2005, European journal of haematology.

[6]  P. Dougherty,et al.  Dysfunction in multiple primary afferent fiber subtypes revealed by quantitative sensory testing in patients with chronic vincristine-induced pain. , 2007, Journal of pain and symptom management.

[7]  Alan Gordon,et al.  Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma. , 2004, Journal of the National Cancer Institute.

[8]  W. Trojaborg,et al.  Electrophysiological study of the peripheral and central neurotoxic effect of cis‐platin , 1987, Acta neurologica Scandinavica.

[9]  G. Cavaletti,et al.  Cisplatin-induced DNA-platination in experimental dorsal root ganglia neuronopathy. , 1999, Neurotoxicology.

[10]  A. Caraceni,et al.  The Total Neuropathy Score as an assessment tool for grading the course of chemotherapy‐induced peripheral neurotoxicity: comparison with the National Cancer Institute‐Common Toxicity Scale , 2007, Journal of the peripheral nervous system : JPNS.

[11]  A. Argyriou,et al.  Preventing paclitaxel-induced peripheral neuropathy: a phase II trial of vitamin E supplementation. , 2006, Journal of pain and symptom management.

[12]  J. Baselga,et al.  Phase II genomics study of ixabepilone as neoadjuvant treatment for breast cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  A. Grothey,et al.  Use of calcium and magnesium salts to reduce oxaliplatin-related neurotoxicity. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  I. Yakoub-Agha,et al.  Peripheral neuropathy and new treatments for multiple myeloma: background and practical recommendations , 2010, Haematologica.

[15]  J. Crowley,et al.  Evaluation of cisplatin intensity in metastatic non-small-cell lung cancer: a phase III study of the Southwest Oncology Group. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  L. Crinò,et al.  A Pilot Study on the Effect of Acetyl-L-Carnitine in Paclitaxel-And Cisplatin-Induced Peripheral Neuropathy , 2005, Tumori.

[17]  R. Herbst,et al.  A phase I safety and pharmacokinetic (PK) study of recombinant Apo2L/TRAIL, an apoptosis-inducing protein in patients with advanced cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  D. Dearnaley,et al.  Long‐term neurologic and peripheral vascular toxicity after chemotherapy treatment of testicular cancer , 2010, Cancer.

[19]  E. Lazarides,et al.  Epothilones, a new class of microtubule-stabilizing agents with a taxol-like mechanism of action. , 1995, Cancer research.

[20]  A. Argyriou,et al.  A review on oxaliplatin-induced peripheral nerve damage. , 2008, Cancer treatment reviews.

[21]  G. Nicolini,et al.  Morphological and morphometric analysis of paclitaxel and docetaxel-induced peripheral neuropathy in rats. , 2005, European journal of cancer.

[22]  A. Argyriou,et al.  Incidence and characteristics of peripheral neuropathy during oxaliplatin-based chemotherapy for metastatic colon cancer , 2007, Acta oncologica.

[23]  C. Liao,et al.  Chronomodulated chemotherapy versus conventional chemotherapy for advanced colorectal cancer: a meta-analysis of five randomized controlled trials , 2010, International Journal of Colorectal Disease.

[24]  J. Walewski,et al.  CHOP-21 for unfavorable Hodgkin’s lymphoma. An exploratory study , 2010, Medical oncology.

[25]  D. Esseltine,et al.  Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase 1/2 study. , 2006, Blood.

[26]  A. Pace,et al.  Vinorelbine neurotoxicity: clinical and neurophysiological findings in 23 patients. , 1996, Journal of neurology, neurosurgery, and psychiatry.

[27]  E. Vokes,et al.  A phase II trial of the epothilone B analog, BMS-247550, in patients with previously treated advanced colorectal cancer. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

[28]  Kevin D. Nullmeyer,et al.  Mitochondrial-mediated disregulation of Ca2+ is a critical determinant of Velcade (PS-341/bortezomib) cytotoxicity in myeloma cell lines. , 2005, Cancer research.

[29]  E. Bandrés,et al.  Oxaliplatin, irinotecan and capecitabine as first-line therapy in metastatic colorectal cancer (mCRC): a dose-finding study and pharmacogenomic analysis , 2010, British Journal of Cancer.

[30]  S. Studenski,et al.  Persistent Mobility Disability After Neurotoxic Chemotherapy , 2010, Physical Therapy.

[31]  A. Knight,et al.  Cisplatin preferentially binds to DNA in dorsal root ganglion neurons in vitro and in vivo: a potential mechanism for neurotoxicity , 2005, Neurobiology of Disease.

[32]  S. Agelaki,et al.  Triplet combination with irinotecan plus oxaliplatin plus continuous-infusion fluorouracil and leucovorin as first-line treatment in metastatic colorectal cancer: a multicenter phase II trial. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  P. Sonneveld,et al.  A practical update on the use of bortezomib in the management of multiple myeloma. , 2006, The oncologist.

[34]  C. Sawka,et al.  Randomized phase III study of fludarabine phosphate versus cyclophosphamide, vincristine, and prednisone in patients with recurrent low-grade non-Hodgkin's lymphoma previously treated with an alkylating agent or alkylator-containing regimen. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  S. Groshen,et al.  Association between glutathione S-transferase P1, T1, and M1 genetic polymorphism and survival of patients with metastatic colorectal cancer. , 2002, Journal of the National Cancer Institute.

[36]  G. Cavaletti,et al.  Neurotoxicity and ototoxicity of cisplatin plus paclitaxel in comparison to cisplatin plus cyclophosphamide in patients with epithelial ovarian cancer. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  J. Glick,et al.  Amifostine pretreatment for protection against cyclophosphamide-induced and cisplatin-induced toxicities: results of a randomized control trial in patients with advanced ovarian cancer. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  W. Scheithauer,et al.  Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  M. Koltzenburg,et al.  Peripheral nerve damage associated with administration of taxanes in patients with cancer. , 2008, Critical reviews in oncology/hematology.

[40]  H. Earl,et al.  Long-Term Neurotoxicity of Chemotherapy in Adolescents and Young Adults Treated for Bone and Soft Tissue Sarcomas , 1998, Sarcoma.

[41]  H. Kantarjian,et al.  Liposomal vincristine in relapsed non-Hodgkin's lymphomas: early results of an ongoing phase II trial. , 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

[42]  A. Norman,et al.  Capecitabine and oxaliplatin for advanced esophagogastric cancer. , 2008, The New England journal of medicine.

[43]  V. Catalano,et al.  Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFOX-4 chemotherapy. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[44]  C. Bokemeyer,et al.  Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[45]  D. Fishman,et al.  Psychometric evaluation of the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group—Neurotoxicity (Fact/GOG‐Ntx) questionnaire for patients receiving systemic chemotherapy , 2003, International journal of gynecological cancer : official journal of the International Gynecological Cancer Society.

[46]  R. Mandler,et al.  Fulminant demyelinating neuropathy mimicking cerebral death , 1997 .

[47]  M. Zucchetti,et al.  Distribution of paclitaxel within the nervous system of the rat after repeated intravenous administration. , 2000, Neurotoxicology.

[48]  G. Trovato,et al.  [Erythropoietin and cisplatin-induced neuropathies in cancer patients]. , 2002, La Clinica terapeutica.

[49]  D. Restuccia,et al.  Cisplatin neuropathy: clinical course and neurophysiological findings , 1992, Journal of Neurology.

[50]  J. Levine,et al.  Damage to the cytoskeleton of large diameter sensory neurons and myelinated axons in vincristine‐induced painful peripheral neuropathy in the rat , 2000, The Journal of comparative neurology.

[51]  S. Steinberg,et al.  Changes in neurologic function tests may predict neurotoxicity caused by ixabepilone. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[52]  P. Novotny,et al.  Intravenous calcium and magnesium for oxaliplatin-induced sensory neurotoxicity in adjuvant colon cancer: NCCTG N04C7. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[53]  J J Correia,et al.  Interaction of vinca alkaloids with tubulin: a comparison of vinblastine, vincristine, and vinorelbine. , 1996, Biochemistry.

[54]  M. Friedlander,et al.  Oxaliplatin-Induced Lhermitte’s Phenomenon as a Manifestation of Severe Generalized Neurotoxicity , 2009, Oncology.

[55]  A. Argyriou,et al.  Paclitaxel plus carboplatin–induced peripheral neuropathy , 2005, Journal of Neurology.

[56]  M. Dimopoulos,et al.  Treatment of Waldenstrom’s Macroglobulinemia , 2007, Current treatment options in oncology.

[57]  P. Catalano,et al.  Phase III, randomized study of gemcitabine and oxaliplatin versus gemcitabine (fixed-dose rate infusion) compared with gemcitabine (30-minute infusion) in patients with pancreatic carcinoma E6201: a trial of the Eastern Cooperative Oncology Group. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[58]  C. Tournigand,et al.  Oxaliplatin-related neurotoxicity: interest of calcium-magnesium infusion and no impact on its efficacy. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[59]  B. Glimelius,et al.  A randomized study comparing short-time infusion of oxaliplatin in combination with capecitabine XELOX(30) and chronomodulated XELOX(30) as first-line therapy in patients with advanced colorectal cancer. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[60]  D. Stewart,et al.  Cisplatin neurotoxicity: the relationship between dosage, time, and platinum concentration in neurologic tissues, and morphologic evidence of toxicity. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[61]  M. Sereno,et al.  Chemotherapy-induced peripheral neuropathy: clinical features, diagnosis, prevention and treatment strategies , 2010, Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico.

[62]  J. Bogaerts,et al.  Phase III comparative study of high-dose cisplatin versus a combination of paclitaxel and cisplatin in patients with advanced non-small-cell lung cancer. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[63]  T. Ruhstaller,et al.  Heated (37°C) oxaliplatin infusion in combination with capecitabine for metastatic colorectal carcinoma: can it reduce neuropathy? , 2010, Supportive Care in Cancer.

[64]  P. Rougier,et al.  Thermal hyperalgesia as a marker of oxaliplatin neurotoxicity: A prospective quantified sensory assessment study , 2009, PAIN®.

[65]  G. Cavaletti,et al.  Thalidomide sensory neurotoxicity , 2004, Neurology.

[66]  C. Spurr,et al.  Treatment of advanced non‐Hodgkin's lymphoma with vincristine infusion , 1984, Cancer.

[67]  T. Cosgriff,et al.  A phase II study of weekly nanoparticle albumin-bound paclitaxel with or without trastuzumab in metastatic breast cancer. , 2011, Clinical breast cancer.

[68]  K. Altmann,et al.  Synthesis and biological evaluation of highly potent analogues of epothilones B and D. , 2000, Bioorganic & medicinal chemistry letters.

[69]  Alessandro Corso,et al.  Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. , 2007, The New England journal of medicine.

[70]  K. Savin,et al.  Desoxyepothilone B: an efficacious microtubule-targeted antitumor agent with a promising in vivo profile relative to epothilone B. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[71]  E. Mamounas,et al.  Randomized trial of 3-hour versus 24-hour infusion of high-dose paclitaxel in patients with metastatic or locally advanced breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-26. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[72]  P. Thoumie,et al.  How far do patients with sensory ataxia benefit from so-called “proprioceptive rehabilitation”? , 2009, Neurophysiologie Clinique/Clinical Neurophysiology.

[73]  E. Perez,et al.  Weekly paclitaxel in the adjuvant treatment of breast cancer. , 2008, The New England journal of medicine.

[74]  H Irschik,et al.  Epothilons A and B: antifungal and cytotoxic compounds from Sorangium cellulosum (Myxobacteria). Production, physico-chemical and biological properties. , 1996, The Journal of antibiotics.

[75]  D. Sargent,et al.  Pharmacogenetic predictors of adverse events and response to chemotherapy in metastatic colorectal cancer: results from North American Gastrointestinal Intergroup Trial N9741. , 2010, Journal of Clinical Oncology.

[76]  J. Heimans,et al.  Dose-related vincristine-induced peripheral neuropathy with unexpected off-therapy worsening , 2005, Neurology.

[77]  A. Argyriou,et al.  Vitamin E for preventing chemotherapy-induced peripheral neuropathy , 2011, Supportive Care in Cancer.

[78]  T. Hickish,et al.  Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. , 2004, The New England journal of medicine.

[79]  M. Floeter,et al.  Acute oxaliplatin-induced peripheral nerve hyperexcitability. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[80]  B. Smoller,et al.  Targeting human 8-oxoguanine DNA glycosylase (hOGG1) to mitochondria enhances cisplatin cytotoxicity in hepatoma cells. , 2007, Carcinogenesis.

[81]  Krarup,et al.  Histology and platinum content of sensory ganglia and sural nerves in patients treated with cisplatin and carboplatin: an autopsy study , 1999, Neuropathology and applied neurobiology.

[82]  A. Windebank,et al.  Cisplatin-induced apoptosis in rat dorsal root ganglion neurons is associated with attempted entry into the cell cycle. , 1998, The Journal of clinical investigation.

[83]  P. Dougherty,et al.  Quantitative sensory findings in patients with bortezomib-induced pain. , 2007, The journal of pain : official journal of the American Pain Society.

[84]  G. Cavaletti,et al.  Thalidomide chemotherapy-induced peripheral neuropathy: actual status and new perspectives with thalidomide analogues derivatives. , 2009, Mini reviews in medicinal chemistry.

[85]  Low-Dose Thalidomide for Multiple Myeloma: Interim Analysis of a Compassionate Use Program , 2004, Oncology Research and Treatment.

[86]  J. Heimans,et al.  Long term effects of vincristine on the peripheral nervous system , 2005, Journal of Neuro-Oncology.

[87]  J. Heimans,et al.  A pilot study on the influence of a corticotropin (4-9) analogue on Vinca alkaloid-induced neuropathy. , 1992, Archives of neurology.

[88]  F. Lévi,et al.  Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[89]  D. Esseltine,et al.  Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose‐modification guideline , 2009, British journal of haematology.

[90]  C. Bokemeyer,et al.  Evaluation of long-term toxicity after chemotherapy for testicular cancer. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[91]  Jun Liang,et al.  Genetic Polymorphism of GSTP1: Prediction of Clinical Outcome to Oxaliplatin/5-FU-based Chemotherapy in Advanced Gastric Cancer , 2010, Journal of Korean medical science.

[92]  K. Swenerton,et al.  Cisplatin-cyclophosphamide versus carboplatin-cyclophosphamide in advanced ovarian cancer: a randomized phase III study of the National Cancer Institute of Canada Clinical Trials Group. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[93]  A. Zelenetz,et al.  A multicentre phase II clinical experience with the novel aza‐epothilone Ixabepilone (BMS247550) in patients with relapsed or refractory indolent non‐Hodgkin lymphoma and mantle cell lymphoma , 2008, British journal of haematology.

[94]  T. Bird,et al.  Severe vincristine neuropathy in charcot‐marie‐tooth disease type 1A , 1996 .

[95]  J. C. Houwelingen,et al.  Prevention of cisplatin neurotoxicity with an ACTH (4–9) analogue in patients with ovarian cancer , 1990 .

[96]  H. Reichenbach,et al.  New natural epothilones from Sorangium cellulosum, strains So ce90/B2 and So ce90/D13: isolation, structure elucidation, and SAR studies. , 2001, Journal of natural products.

[97]  H. Diener,et al.  Lack of neuroprotection by an ACTH (4–9) analogue. A randomized trial in patients treated with vincristine for Hodgkin’s or non-Hodgkin’s lymphoma , 2004, Journal of Cancer Research and Clinical Oncology.

[98]  Diane Warren,et al.  A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. , 2006, Blood.

[99]  H. Groen,et al.  First-line gemcitabine with cisplatin or epirubicin in advanced non-small-cell lung cancer: a phase III trial , 2003, British Journal of Cancer.

[100]  R. Labianca,et al.  Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[101]  E. Alba,et al.  'Out of blue' Lhermitte's sign: three cases due to low cumulative doses of oxaliplatin. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[102]  D. Berry,et al.  Failure of higher-dose paclitaxel to improve outcome in patients with metastatic breast cancer: cancer and leukemia group B trial 9342. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[103]  D. Esseltine,et al.  Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[104]  P. Ott,et al.  A Phase II Trial of the Epothilone B Analog Ixabepilone (BMS-247550) in Patients with Metastatic Melanoma , 2010, PloS one.

[105]  G. Cavaletti,et al.  Chemotherapy-Induced Peripheral Neurotoxicity assessment: a critical revision of the currently available tools. , 2010, European journal of cancer.

[106]  H. Gelderblom,et al.  Pharmacology of oxaliplatin and the use of pharmacogenomics to individualize therapy. , 2005, Cancer treatment reviews.

[107]  Michael L. Wang,et al.  Multiple Myeloma, Painful Neuropathy, Acupuncture? , 2009, American journal of clinical oncology.

[108]  S. Steinberg,et al.  Phase II trial of ixabepilone, an epothilone B analog, given daily for three days every three weeks, in metastatic breast cancer , 2006, Investigational New Drugs.

[109]  H. Chung,et al.  Docetaxel versus paclitaxel combined with 5-FU and leucovorin in advanced gastric cancer: combined analysis of two phase II trials. , 2009, Cancer research and treatment : official journal of Korean Cancer Association.

[110]  M. Friedlander,et al.  Oxaliplatin-induced neurotoxicity: changes in axonal excitability precede development of neuropathy. , 2009, Brain : a journal of neurology.

[111]  T. Miyazaki,et al.  Effect of calcium and magnesium on neurotoxicity and blood platinum concentrations in patients receiving mFOLFOX6 therapy: a prospective randomized study , 2010, International Journal of Clinical Oncology.

[112]  D. Esseltine,et al.  Single-agent bortezomib in previously untreated multiple myeloma: efficacy, characterization of peripheral neuropathy, and molecular correlations with response and neuropathy. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[113]  M. Loriot,et al.  Glutathione S-Transferase P1 Polymorphism (Ile105Val) Predicts Cumulative Neuropathy in Patients Receiving Oxaliplatin-Based Chemotherapy , 2006, Clinical Cancer Research.

[114]  A. Ranganathan,et al.  Highlights From: the 2006 American Society of Clinical Oncology Gastrointestinal Cancers Symposium San Francisco, CA, January 2006. , 2006, Clinical colorectal cancer.

[115]  L. Padua,et al.  Multi‐center assessment of the Total Neuropathy Score for chemotherapy‐induced peripheral neurotoxicity , 2006, Journal of the peripheral nervous system : JPNS.

[116]  D. Cornblath,et al.  Characteristics of bortezomib‐ and thalidomide‐induced peripheral neuropathy , 2008, Journal of the peripheral nervous system : JPNS.

[117]  R. Gascoyne,et al.  Vincristine sulfate liposomes injection (Marqibo) in heavily pretreated patients with refractory aggressive non‐Hodgkin lymphoma , 2009, Cancer.

[118]  T. Boulikas Low toxicity and anticancer activity of a novel liposomal cisplatin (Lipoplatin) in mouse xenografts. , 2004, Oncology reports.

[119]  M. Friedlander,et al.  Mechanisms underlying chemotherapy-induced neurotoxicity and the potential for neuroprotective strategies. , 2008, Current medicinal chemistry.

[120]  Charles W. Taylor,et al.  Combination chemotherapy with cyclophosphamide, vincristine, adriamycin, and dexamethasone (CVAD) plus oral quinine and verapamil in patients with advanced breast cancer , 2004, Breast Cancer Research and Treatment.

[121]  D. Lake,et al.  Phase II trial of weekly nanoparticle albumin-bound paclitaxel with carboplatin and trastuzumab as first-line therapy for women with HER2-overexpressing metastatic breast cancer. , 2010, Clinical breast cancer.

[122]  D. Crowther,et al.  Five year follow-up and dose delivery analysis of cisplatin, iproplatin or carboplatin in combination with cyclophosphamide in advanced ovarian carcinoma. , 1990, Annals of Oncology.

[123]  A. Argyriou,et al.  Clinical and electrophysiological features of peripheral neuropathy induced by administration of cisplatin plus paclitaxel-based chemotherapy. , 2007, European journal of cancer care.

[124]  O. Dalesio,et al.  Cisplatin induced neuropathy: Central, peripheral and autonomic nerve involvement , 1990, Journal of Neuro-Oncology.

[125]  M. Kelley,et al.  Implications of apurinic/apyrimidinic endonuclease in reactive oxygen signaling response after cisplatin treatment of dorsal root ganglion neurons. , 2008, Cancer research.

[126]  A. Argyriou,et al.  Bortezomib-induced peripheral neuropathy in multiple myeloma: a comprehensive review of the literature. , 2008, Blood.

[127]  A. Palumbo,et al.  Thalidomide neuropathy: clinical, electrophysiological and neuroradiological features , 2004, Acta neurologica Scandinavica.

[128]  A. Windebank,et al.  Neurotoxicity of oxaliplatin and cisplatin for dorsal root ganglion neurons correlates with platinum-DNA binding. , 2006, Neurotoxicology.

[129]  M. Ermani,et al.  Thalidomide neurotoxicity , 2004, Neurology.

[130]  J. Shafer,et al.  Reaction pathway for inhibition of blood coagulation factor Xa by tick anticoagulant peptide. , 1992, Biochemistry.

[131]  G. Sutton,et al.  A phase III trial of ifosfamide with or without cisplatin in carcinosarcoma of the uterus: A Gynecologic Oncology Group Study. , 2000, Gynecologic oncology.

[132]  D. Cella,et al.  Limited access trial using amifostine for protection against cisplatin- and three-hour paclitaxel-induced neurotoxicity: a phase II study of the Gynecologic Oncology Group. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[133]  J. Manola,et al.  Phase 2 trial of epothilone B analog BMS‐247550 (ixabepilone) in advanced carcinoma of the urothelium (E3800) , 2007, Cancer.

[134]  J. Rogin,et al.  Peripheral sensory neuropathy and cisplatin chemotherapy , 1984, Neurology.

[135]  A. Silvani,et al.  Vitamin E neuroprotection for cisplatin neuropathy , 2010, Neurology.

[136]  J. Sloan,et al.  The use of vitamin E for the prevention of chemotherapy-induced peripheral neuropathy: results of a randomized phase III clinical trial , 2011, Supportive Care in Cancer.

[137]  K. Kitagawa,et al.  Associations between oxaliplatin-induced peripheral neuropathy and polymorphisms of the ERCC1 and GSTP1 genes. , 2010, International journal of clinical pharmacology and therapeutics.

[138]  D Grob,et al.  Vincristine treatment of advanced cancer: a cooperative study of 392 cases. , 1973, Cancer research.

[139]  M. J. van den Bent,et al.  Retreatment with dose-dense weekly cisplatin after previous cisplatin chemotherapy is not complicated by significant neuro-toxicity. , 2002, European journal of cancer.

[140]  A. Argyriou,et al.  Is advanced age associated with increased incidence and severity of chemotherapy-induced peripheral neuropathy? , 2006, Supportive Care in Cancer.

[141]  F. Matsuda,et al.  Associations between glutathione S-transferase pi Ile105Val and glyoxylate aminotransferase Pro11Leu and Ile340Met polymorphisms and early-onset oxaliplatin-induced neuropathy. , 2010, Cancer epidemiology.

[142]  S. Steinberg,et al.  Phase II trial of ixabepilone, an epothilone B analog, in patients with metastatic breast cancer previously untreated with taxanes. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[143]  E K Rowinsky,et al.  Phase I and pharmacologic study of paclitaxel and cisplatin with granulocyte colony-stimulating factor: neuromuscular toxicity is dose-limiting. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[144]  R. Eeles,et al.  Lhermitte's sign as a complication of cisplatin-containing chemotherapy for testicular cancer. , 1986, Cancer treatment reports.

[145]  T. Aoki,et al.  Clinical effects of combination therapy with mitoxantrone, vincristine, and prednisolone in breast cancer , 2003, Cancer Chemotherapy and Pharmacology.

[146]  Jin-Hwang Liu,et al.  Oral glutamine is effective for preventing oxaliplatin-induced neuropathy in colorectal cancer patients. , 2007, The oncologist.

[147]  Wolfgang Grisold,et al.  Chemotherapy‐induced neuropathy , 2008, Journal of the peripheral nervous system : JPNS.

[148]  M. Rocchi,et al.  High activity and reduced neurotoxicity of bi-fractionated oxaliplatin plus 5-fluorouracil/leucovorin for elderly patients with advanced colorectal cancer. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

[149]  J. Berlin,et al.  Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trial. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[150]  Sindhu Ramchandren,et al.  Peripheral neuropathy in survivors of childhood acute lymphoblastic leukemia , 2009, Journal of the peripheral nervous system : JPNS.

[151]  J. Albanell,et al.  The proteasome: a novel target for anticancer therapy , 2006, Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico.

[152]  G. Pond,et al.  Phase II study of pegylated liposomal doxorubicin HCl (Caelyx) in combination with cyclophosphamide and vincristine as second-line treatment of patients with small cell lung cancer. , 2003, Lung cancer.

[153]  J. Gralow,et al.  Phase I/II study of ixabepilone plus capecitabine in anthracycline-pretreated/resistant and taxane-resistant metastatic breast cancer. , 2008, Clinical breast cancer.

[154]  S. Swain,et al.  Peripheral neuropathy induced by microtubule-stabilizing agents. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[155]  A. Windebank,et al.  Cisplatin-Induced Apoptosis of DRG Neurons Involves Bax Redistribution and Cytochrome c Release But Not fas Receptor Signaling , 2002, Neurobiology of Disease.

[156]  J. Crowley,et al.  Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small-cell lung cancer: a Southwest Oncology Group study. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[157]  S. Brady,et al.  Axonal tubulin and microtubules: morphologic evidence for stable regions on axonal microtubules. , 1987, Cell motility and the cytoskeleton.

[158]  J. Heimans,et al.  Peripheral neuropathy due to therapy with paclitaxel, gemcitabine, and cisplatin in patients with advanced ovarian cancer , 2003, Journal of Neuro-Oncology.

[159]  R. Labianca,et al.  Neuroprotective effect of reduced glutathione on oxaliplatin-based chemotherapy in advanced colorectal cancer: a randomized, double-blind, placebo-controlled trial. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[160]  P. Giannakakou,et al.  Activities of the Microtubule-stabilizing Agents Epothilones A and B with Purified Tubulin and in Cells Resistant to Paclitaxel (Taxol®)* , 1997, The Journal of Biological Chemistry.

[161]  A. Argyriou,et al.  The usefulness of nerve conduction studies in objectively assessing oxaliplatin-induced peripheral neuropathy. , 2007, The oncologist.

[162]  P. M. L. Quesne,et al.  Vincristine neuropathy. Clinical and electrophysiological observations. , 1973, Brain : a journal of neurology.

[163]  C. Punt,et al.  Glutathione-S-transferase pi (GSTP1) codon 105 polymorphism is not associated with oxaliplatin efficacy or toxicity in advanced colorectal cancer patients. , 2009, European journal of cancer.

[164]  R. Donehower,et al.  Peripheral neuropathy from taxol and cisplatin combination chemotherapy: Clinical and electrophysiological studies , 1994, Annals of neurology.

[165]  G. Cavaletti,et al.  Bortezomib-induced peripheral neurotoxicity: A neurophysiological and pathological study in the rat , 2007, Experimental Neurology.

[166]  J. Verweij,et al.  Docetaxel in 253 previously treated patients with progressive locally advanced or metastatic breast cancer: results of a compassionate use program in The Netherlands , 2000, Anti-Cancer Drugs.

[167]  Hartmut Goldschmidt,et al.  Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. , 2005, The New England journal of medicine.

[168]  G. Bennett,et al.  Prevention of paclitaxel-evoked painful peripheral neuropathy by acetyl-l-carnitine: Effects on axonal mitochondria, sensory nerve fiber terminal arbors, and cutaneous Langerhans cells , 2008, Experimental Neurology.

[169]  S. Rossi,et al.  Thalidomide-induced neuropathy: A ganglionopathy? , 2003, Neurology.

[170]  A. Argyriou,et al.  Efficacy of oxcarbazepine for prophylaxis against cumulative oxaliplatin-induced neuropathy , 2006, Neurology.

[171]  E. Perez,et al.  Efficacy and safety of ixabepilone (BMS-247550) in a phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabine. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[172]  M. Fukuoka,et al.  A randomized study of cisplatin versus cisplatin plus vindesine for non‐small cell lung carcinoma , 1991, Cancer.

[173]  C. Bokemeyer,et al.  Pharmacogenetic analyses of a phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil and leucovorin plus either oxaliplatin or cisplatin: a study of the arbeitsgemeinschaft internistische onkologie. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[174]  I. Judson,et al.  A randomised trial comparing combination chemotherapy using mitomycin C, mitozantrone and methotrexate (3M) with vincristine, anthracycline and cyclophosphamide (VAC) in advanced breast cancer. , 1991, British Journal of Cancer.

[175]  G. Cavaletti,et al.  Chemotherapy-induced peripheral neurotoxicity , 2004, Expert opinion on drug safety.

[176]  M. Floeter,et al.  Oxaliplatin‐induced neurotoxicity: Acute hyperexcitability and chronic neuropathy , 2004, Muscle & nerve.

[177]  J. Baselga,et al.  Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in patients with taxane-resistant metastatic breast cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[178]  J. Blessing,et al.  A Phase II Trial of Vincristine in Advanced or Recurrent Endometrial Carcinoma A Gynecologic Oncology Group Study , 1993, American journal of clinical oncology.

[179]  C. Leonetti,et al.  Neuroprotective effect of vitamin E supplementation in patients treated with cisplatin chemotherapy. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[180]  M. Leandri,et al.  Persistence of High-Dose Oxaliplatin-Induced Neuropathy at Long-Term Follow-Up , 2006, European Neurology.

[181]  J. Kopec,et al.  Neurotoxicity from oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: NSABP C-07. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[182]  J. Slingerland,et al.  Final results of a phase II study of nab-paclitaxel, bevacizumab, and gemcitabine as first-line therapy for patients with HER2-negative metastatic breast cancer , 2010, Breast Cancer Research and Treatment.

[183]  H. Kaube,et al.  Repair Capacity for Platinum-DNA Adducts Determines the Severity of Cisplatin-Induced Peripheral Neuropathy , 2007, The Journal of Neuroscience.

[184]  R. Ramlau,et al.  Phase III trial comparing vinflunine with docetaxel in second-line advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[185]  P. Bouche,et al.  Incidence and risk factors for thalidomide neuropathy: a prospective study of 135 dermatologic patients. , 2002, The Journal of investigative dermatology.

[186]  M. Spira,et al.  Paclitaxel induces axonal microtubules polar reconfiguration and impaired organelle transport: implications for the pathogenesis of paclitaxel-induced polyneuropathy , 2010, Acta Neuropathologica.

[187]  H. Gómez,et al.  Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[188]  P. Mantyh,et al.  An evolving cellular pathology occurs in dorsal root ganglia, peripheral nerve and spinal cord following intravenous administration of paclitaxel in the rat , 2007, Brain Research.

[189]  C. Wilson,et al.  Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[190]  T. Boulikas,et al.  First safety and response results of a randomized phase III study with liposomal platin in the treatment of advanced squamous cell carcinoma of the head and neck (SCCHN). , 2007, Anticancer research.

[191]  L. Deangelis,et al.  Evolution of neuropathy and myopathy during intensive vincristine/corticosteroid chemotherapy for non‐hodgkin's lymphoma , 1991, Cancer.

[192]  Xavier Navarro,et al.  Neurological monitoring reduces the incidence of bortezomib‐induced peripheral neuropathy in multiple myeloma patients , 2010, Journal of the peripheral nervous system : JPNS.

[193]  C. Tournigand,et al.  OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-Go fashion in advanced colorectal cancer--a GERCOR study. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[194]  C. Higano,et al.  Phase II study of KOS-862 in patients with metastatic androgen independent prostate cancer previously treated with docetaxel , 2007, Investigational New Drugs.

[195]  J. Lotz,et al.  High-dose intensity oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX 7). , 2001, European journal of cancer.

[196]  G. Cavaletti,et al.  Bortezomib‐induced painful neuropathy in rats: A behavioral, neurophysiological and pathological study in rats , 2010, European journal of pain.

[197]  A. Lissoni,et al.  Grading of chemotherapy-induced peripheral neurotoxicity using the Total Neuropathy Scale , 2003, Neurology.

[198]  L. Davis,et al.  Cisplatin neuropathy. Clinical, electrophysiologic, morphologic, and toxicologic studies , 1984, Cancer.

[199]  P. Dyck,et al.  Vinca alkaloid neuropathy , 1968, Neurology.

[200]  J. Holland,et al.  Comparison of psychosocial adaptation and sexual function of survivors of advanced hodgkin disease treated by MOPP, ABVD, or MOPP alternating with ABVD , 1992, Cancer.

[201]  D. Rosenthal,et al.  Chlorambucil, vinblastine, procarbazine, and prednisone. An effective but less toxic regimen than MOPP for advanced‐stage Hodgkin's disease , 1989, Cancer.

[202]  J. Minna,et al.  Possible enhancement of vincristine neuropathy by VP‐16 , 1982, Cancer.

[203]  A. Valachis,et al.  Overall survival benefit for weekly vs. three-weekly taxanes regimens in advanced breast cancer: A meta-analysis. , 2010, Cancer treatment reviews.

[204]  N. Petrelli,et al.  Initial safety report of NSABP C-08: A randomized phase III study of modified FOLFOX6 with or without bevacizumab for the adjuvant treatment of patients with stage II or III colon cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[205]  S. Culine,et al.  A phase II study of vinflunine in bladder cancer patients progressing after first-line platinum-containing regimen , 2006, British Journal of Cancer.

[206]  H. Reinders-Messelink,et al.  Mild axonal neuropathy of children during treatment for acute lymphoblastic leukaemia. , 2000, European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society.

[207]  T. Fojo,et al.  A Phase II Clinical Trial of Ixabepilone (Ixempra; BMS-247550; NSC 710428), an Epothilone B Analog, in Patients with Metastatic Renal Cell Carcinoma , 2010, Clinical Cancer Research.

[208]  A. Troxel,et al.  Glutamine as a neuroprotective agent in high-dose paclitaxel-induced peripheral neuropathy: a clinical and electrophysiologic study. , 2005, Clinical oncology (Royal College of Radiologists (Great Britain)).

[209]  D. Strumberg,et al.  Evaluation of long-term toxicity in patients after cisplatin-based chemotherapy for non-seminomatous testicular cancer. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

[210]  J. Mendell,et al.  Studies on the pathogenesis of vincristine‐induced neuropathy , 1987, Muscle & nerve.

[211]  A. Argyriou,et al.  Vitamin E for prophylaxis against chemotherapy-induced neuropathy , 2005, Neurology.

[212]  A. Argyriou,et al.  Integrin beta‐3 L33P: a new insight into the pathogenesis of chronic oxaliplatin‐induced peripheral neuropathy? , 2010, European journal of neurology.

[213]  J. Glass,et al.  Interleukin-6 protects against paclitaxel, cisplatin and vincristine-induced neuropathies without impairing chemotherapeutic activity , 2008, Cancer Chemotherapy and Pharmacology.

[214]  J. Albers,et al.  Interventions for preventing neuropathy caused by cisplatin and related compounds. , 2014, The Cochrane database of systematic reviews.

[215]  M. Socinski,et al.  Phase II clinical trial of the epothilone B analog, ixabepilone, in patients with non small-cell lung cancer whose tumors have failed first-line platinum-based chemotherapy. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[216]  R. Penny,et al.  Vincristine neuropathy: an electrophysiological and histological study. , 1969, Journal of neurology, neurosurgery, and psychiatry.

[217]  T. Boulikas,et al.  Pharmacokinetics and adverse reactions of a new liposomal cisplatin (Lipoplatin): phase I study. , 2005, Oncology reports.

[218]  J. Levine,et al.  Microtubule disorientation and axonal swelling in unmyelinated sensory axons during vincristine‐induced painful neuropathy in rat , 1998, The Journal of comparative neurology.

[219]  J. Gilsbach,et al.  Inadvertent intrathecal vincristine administration: a neurosurgical emergency. Case report. , 2007, Journal of neurosurgery. Spine.

[220]  H. Dombret,et al.  High-dose imatinib mesylate combined with vincristine and dexamethasone (DIV regimen) as induction therapy in patients with resistant Philadelphia-positive acute lymphoblastic leukemia and lymphoid blast crisis of chronic myeloid leukemia , 2006, Leukemia.

[221]  Michael Wang,et al.  Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. , 2007, The New England journal of medicine.

[222]  W. Figg,et al.  Thalidomide metabolism and hydrolysis: mechanisms and implications. , 2006, Current drug metabolism.

[223]  G. Cavaletti,et al.  Effects of different schedules of oxaliplatin treatment on the peripheral nervous system of the rat. , 2001, European journal of cancer.

[224]  J. Sparano,et al.  Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, as first-line therapy in patients with metastatic breast cancer previously treated with anthracycline chemotherapy. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[225]  G. Cavaletti,et al.  Effect on the peripheral nervous system of the short-term intravenous administration of paclitaxel in the rat. , 1997, Neurotoxicology.

[226]  M. Berciano,et al.  Bortezomib Induces the Formation of Nuclear poly(A) RNA Granules Enriched in Sam68 and PABPN1 in Sensory Ganglia Neurons , 2010, Neurotoxicity Research.

[227]  A. Rapoport,et al.  Neurotoxicity of bortezomib therapy in multiple myeloma: A single‐center experience and review of the literature , 2007, Cancer.

[228]  J. Schellens,et al.  Persistent neuropathy after treatment with cisplatin and oxaliplatin , 2009, Acta oncologica.

[229]  E. Gamelin,et al.  A possible explanation for a neurotoxic effect of the anticancer agent oxaliplatin on neuronal voltage-gated sodium channels. , 2001, Journal of neurophysiology.

[230]  D. Cella,et al.  A randomized phase III trial in advanced endometrial carcinoma of surgery and volume directed radiation followed by cisplatin and doxorubicin with or without paclitaxel: A Gynecologic Oncology Group study. , 2009, Gynecologic oncology.

[231]  F. Goldwasser,et al.  Exacerbation of oxaliplatin neurosensory toxicity following surgery. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

[232]  M. Friedlander,et al.  Oxaliplatin‐induced neurotoxicity and the development of neuropathy , 2005, Muscle & nerve.

[233]  G. Cavaletti,et al.  Carboplatin toxic effects on the peripheral nervous system of the rat. , 1998, Annals of oncology : official journal of the European Society for Medical Oncology.

[234]  X. Navarro,et al.  Neurophysiological, histological and immunohistochemical characterization of bortezomib-induced neuropathy in mice , 2010, Experimental Neurology.

[235]  M. Miloso,et al.  Role of MAPKs in platinum-induced neuronal apoptosis. , 2009, Neurotoxicology.

[236]  Roy E. Furman,et al.  Cisplatin neuropathy. Risk factors, prognosis, and protection by WR‐2721 , 1988, Cancer.

[237]  G. Cavaletti,et al.  Cisplatin‐lnduced peripheral neurotoxicity is dependent on total‐dose intensity and single‐dose intensity , 1992, Cancer.

[238]  D. Crowther,et al.  Original article: Five year follow-up and dose delivery analysis of cisplatin, iproplatin or carboplatin in combination with cyclophosphamide in advanced ovarian carcinoma , 1990 .

[239]  Howard L McLeod,et al.  Platinum neurotoxicity pharmacogenetics , 2009, Molecular Cancer Therapeutics.

[240]  R. Burger,et al.  Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group Study. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[241]  J. Lacy,et al.  Phase II trial of docetaxel-irinotecan combination in advanced esophageal cancer. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

[242]  R. G. van der Hoop,et al.  Incidence of neuropathy in 395 patients with ovarian cancer treated with or without cisplatin , 1990, Cancer.

[243]  G. Cavaletti,et al.  Role of a pre‐existing neuropathy on the course of bortezomib‐induced peripheral neurotoxicity , 2008, Journal of the peripheral nervous system : JPNS.